Search results
Results From The WOW.Com Content Network
Alpha blockers can treat a small range of diseases such as hypertension, Raynaud's disease, benign prostatic hyperplasia (BPH) and erectile dysfunction. [2] Generally speaking, these treatments function by binding an α-blocker to α receptors in the arteries and smooth muscle.
Patients with secondary Raynaud's can also have symptoms related to their underlying diseases. Raynaud's phenomenon is the initial symptom that presents for 70% of patients with scleroderma, a skin and joint disease. [citation needed] When Raynaud's phenomenon is limited to one hand or one foot, it is referred to as unilateral Raynaud's.
Alpha 1 blockers cause vasodilation by relaxing smooth muscles that control blood vessel diameter, leading to lower blood pressure. [1] FDA-approved uses of these drugs include treating conditions like benign prostatic hyperplasia, hypertension, pheochromocytoma, extravasation management, and reversal of local anesthesia.
It was the first alpha blocker which was used for treating Benign Prostatic Hyperplasia. [22] Another Alpha Blocker Prazosin, which was the first drug selective to alpha 1 receptor, was developed in 1987 [22] for the therapy of Benign Prostatic Hyperplasia. Other alpha blockers are then introduced for several diseases. [22]
Prazosin is an α 1-blocker that acts as a non-selective inverse agonist at α 1-adrenergic receptors, including of the α 1A-, α 1B-, and α 1D-adrenergic receptor subtypes. [24] It binds to these receptors with affinity (K i ) values of 0.13 to 1.0 nM for the α 1Α -adrenergic receptor, 0.06 to 0.62 nM for the α 1B -adrenergic receptor ...
Moxonidine is a new-generation alpha-2/imidazoline receptor agonist antihypertensive drug licensed for the treatment of mild to moderate essential hypertension. [5] [6] It may have a role when thiazides, beta-blockers, ACE inhibitors, and calcium channel blockers are not appropriate or have failed to control blood pressure.
Moxisylyte, also known as thymoxamine, is a drug used in urology for the treatment of erectile dysfunction. [1] It is an α 1-adrenergic antagonist. [2] In the United Kingdom, Moxisylte is marketed as Opilon (Archimedes Pharma UK Ltd) and is used for the short-term treatment of primary Raynaud's syndrome.
The term Raynaud's does this and is the term used by the NIH. This ref specifically says "People who have primary Raynaud's (Raynaud's disease) or secondary Raynaud's (Raynaud's phenomenon)" Doc James (talk · contribs · email) 17:36, 1 October 2016 (UTC) Support this is the ICD10 preferred name. We and all medical naming conventions are ...